|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng R, Zhang S, Zeng H, Wang S, Sun K,
Chen R, Li L, Wei W and He J: Cancer incidence and mortality in
China, 2016. J Natl Cancer Cent. 2:1–9. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Duma N, Santana-Davila R and Molina JR:
Non-Small cell lung cancer: Epidemiology, screening, diagnosis, and
treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nan X, Xie C, Yu X and Liu J: EGFR TKI as
First-line treatment for patients with advanced EGFR
mutation-positive non-small-cell lung cancer. Oncotarget.
8:75712–75726. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang CY, Yang JC and Yang PC: Precision
management of advanced Non-small cell lung cancer. Annu Rev Med.
71:117–136. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitchell RA, Luwor RB and Burgess AW:
Epidermal growth factor receptor: Structure-function informing the
design of anticancer therapeutics. Exp Cell Res. 371:1–19. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hellyer JA, White MN, Gardner RM, Cunanan
K, Padda SK, Das M, Ramchandran K, Neal JW and Wakelee HA: Impact
of tumor suppressor gene Co-mutations on differential response to
EGFR TKI therapy in EGFR L858R and exon 19 deletion lung cancer.
Clin Lung Cancer. 23:264–272. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hong W, Wu Q, Zhang J and Zhou Y:
Prognostic value of EGFR 19-del and 21-L858R mutations in patients
with non-small cell lung cancer. Oncol Lett. 18:3887–3895.
2019.PubMed/NCBI
|
|
9
|
Tsai MF, Chang TH, Wu SG, Yang HY, Hsu YC,
Yang PC and Shih JY: EGFR-L858R mutant enhances lung adenocarcinoma
cell invasive ability and promotes malignant pleural effusion
formation through activation of the CXCL12-CXCR4 pathway. Sci Rep.
5:135742015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang T, Zheng L, Wang Q and Xiao S:
Single-cell analyses reveal tumor microenvironment differences
between EGFR 19del and L858R mutations in lung adenocarcinoma. J
Thorac Oncol. 17 (Suppl):S6062022. View Article : Google Scholar
|
|
11
|
Rossi A and Mari E: EGFR-Mutant Non-small
cell lung cancer: State-of-the-Art and future perspectives. EMJ.
7:112–122. 2022.
|
|
12
|
Abourehab MAS, Alqahtani AM, Youssif BGM
and Gouda AM: Globally approved EGFR inhibitors: Insights into
their syntheses, target kinases, biological activities, receptor
interactions, and metabolism. Molecules. 26:66772021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Amelia T, Kartasasmita RE, Ohwada T and
Tjahjono DH: Structural insight and development of EGFR tyrosine
kinase inhibitors. Molecules. 27:8192022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Girard N: Optimizing outcomes in EGFR
mutation-positive NSCLC: Which tyrosine kinase inhibitor and when?
Future Oncol. 14:1117–1132. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fukuoka M, Wu YL, Thongprasert S,
Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu
DT, Saijo N, et al: Biomarker analyses and final overall survival
results from a phase III, randomized, open-label, first-line study
of gefitinib versus carboplatin/paclitaxel in clinically selected
patients with advanced non-small-cell lung cancer in Asia (IPASS).
J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong
Z, Lu S, Cheng Y, Han B, Chen L, et al: First-line erlotinib versus
gemcitabine/cisplatin in patients with advanced EGFR
mutation-positive non-small-cell lung cancer: Analyses from the
phase III, randomized, open-label, ENSURE study. Ann Oncol.
26:1883–1889. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi YK, Wang L, Han BH, Li W, Yu P, Liu
YP, Ding CM, Song X, Ma ZY, Ren XL, et al: First-line icotinib
versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for
patients with advanced EGFR mutation-positive lung adenocarcinoma
(CONVINCE): A phase 3, open-label, randomized study. Ann Oncol.
28:2443–2450. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Zhang L, Jiang D, Wang Y, Zang A,
Ding C, Zhao M, Su W, Zhang Y, Zhong D, et al: Routine-dose and
High-dose icotinib in patients with advanced Non-small cell lung
cancer harboring EGFR Exon 21-L858R mutation: The randomized, phase
II, INCREASE trial. Clin Cancer Res. 26:3162–3171. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sequist LV, Yang JC, Yamamoto N, O'Byrne
K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al:
Phase III study of afatinib or cisplatin plus pemetrexed in
patients with metastatic lung adenocarcinoma with EGFR mutations. J
Clin Oncol. 31:3327–3334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang
Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin
plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations
(LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet
Oncol. 15:213–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park K, Tan EH, O'Byrne K, Zhang L, Boyer
M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, et al: Afatinib versus
gefitinib as first-line treatment of patients with EGFR
mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase
2B, open-label, randomised controlled trial. Lancet Oncol.
17:577–589. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Paz-Ares L, Tan EH, O'Byrne K, Zhang L,
Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, et al: Afatinib
versus gefitinib in patients with EGFR mutation-positive advanced
non-small-cell lung cancer: Overall survival data from the phase
IIb LUX-Lung 7 trial. Ann Oncol. 28:270–277. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lau SC, Chooback N, Ho C and Melosky B:
Outcome differences between First- and Second-generation EGFR
inhibitors in advanced EGFR mutated NSCLC in a large
Population-based cohort. Clin Lung Cancer. 20:e576–e583. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa
K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, et al: Dacomitinib
versus gefitinib as first-line treatment for patients with
EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A
randomised, open-label, phase 3 trial. Lancet Oncol. 18:1454–1466.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa
K, Niho S, Lee M, Linke R, Rosell R, Corral J, et al: Improvement
in overall survival in a randomized study that compared dacomitinib
with gefitinib in patients with advanced non-small-cell lung cancer
and EGFR-Activating mutations. J Clin Oncol. 36:2244–2250. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa
K, Niho S, Chawla A, Rosell R, Corral J, Migliorino MR, et al:
Updated overall survival in a randomized study comparing
dacomitinib with gefitinib as First-line treatment in patients with
advanced Non-Small-cell lung cancer and EGFR-activating mutations.
Drugs. 81:257–266. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheng Y, Mok TS, Zhou X, Lu S, Zhou Q,
Zhou J, Du Y, Yu P, Liu X, Hu C, et al: Safety and efficacy of
first-line dacomitinib in Asian patients with EGFR
mutation-positive non-small cell lung cancer: Results from a
randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer.
154:176–185. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pluzanski A, Wu Y, Cheng Y, Zhou X,
Migliorino MR, Niho S, Nakagawa K, Lee KH, Corral J, Rosell R, et
al: Safety and efficacy of first-line dacomitinib in advanced
non-small cell lung cancer by EGFR mutation subtype in ARCHER 1050.
J Thorac Oncol. 16 (Suppl):S617–S618. 2021. View Article : Google Scholar
|
|
31
|
Tanaka H, Sakamoto H, Akita T, Ohyanagi F,
Kawashima Y, Tambo Y, Tanimoto A, Horiike A, Miyauchi E,
Tsuchiya-Kawano Y, et al: Clinical efficacy of dacomitinib in
rechallenge setting for patients with epidermal growth factor
receptor mutant non-small cell lung cancer: A multicenter
retrospective analysis (TOPGAN2020-02). Thorac Cancer.
13:1471–1478. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang S, Wang Y, Wang L, Liu Y, Hu Y, Liu
Z, Yao Y, Liang L, Liu J, Li J, et al: Efficacy and safety of
dacomitinib as first-line treatment for advanced non-small cell
lung cancer (NSCLC) patients with epidermal growth factor receptor
(EGFR) 21L858R mutation: A multicenter, ambispective, consecutive
case-series study. Ann Oncol. 34 (Suppl):S16972023. View Article : Google Scholar
|
|
33
|
Cho BC, Felip E, Spira AI, Girard N, Lee
JS, Lee SH, Ostapenko YV, Danchaivijitr P, Liu B, Alip A, et al:
Amivantamab plus lazertinib vs osimertinib as first-line treatment
in patients with EGFR-mutated, advanced non-small cell lung cancer
(NSCLC): Primary results from MARIPOSA, a phase III, global,
randomized, controlled trial. Ann Oncol. 34 (Suppl):S13062023.
View Article : Google Scholar
|
|
34
|
Ke EE, Zhou Q, Zhang QY, Su J, Chen ZH,
Zhang XC, Xu CR, Yang JJ, Tu HY, Yan HH, et al: A higher proportion
of the EGFR T790M mutation may contribute to the better survival of
patients with exon 19 deletions compared with those with L858R. J
Thorac Oncol. 12:1368–1375. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Soria JC, Ohe Y, Vansteenkiste J,
Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura
F, Nogami N, Kurata T, et al: Osimertinib in untreated EGFR-Mutated
advanced non-small-cell lung cancer. N Engl J Med. 378:113–125.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ramalingam SS, Vansteenkiste J, Planchard
D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y,
Chewaskulyong B, et al: Overall survival with osimertinib in
untreated, EGFR-Mutated advanced NSCLC. N Engl J Med. 382:41–50.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lu S, Dong X, Jian H, Chen J, Chen G, Sun
Y, Ji Y, Wang Z, Shi J, Lu J, et al: AENEAS: A randomized phase III
trial of aumolertinib versus gefitinib as First-Line therapy for
Locally Advanced or MetastaticNon-Small-Cell lung cancer with EGFR
exon 19 deletion or L858R mutations. J Clin Oncol. 40:3162–3171.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sakata Y, Sakata S, Oya Y, Tamiya M,
Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, et al:
Osimertinib as first-line treatment for advanced epidermal growth
factor receptor mutation-positive non-small-cell lung cancer in a
real-world setting (OSI-FACT). Eur J Cancer. 159:144–153. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ito K, Morise M, Wakuda K, Hataji O,
Shimokawaji T, Takahashi K, Furuya N, Takeyama Y, Goto Y, Abe T, et
al: A multicenter cohort study of osimertinib compared with
afatinib as first-line treatment for EGFR-mutated non-small-cell
lung cancer from practical dataset: CJLSG1903. ESMO Open.
6:1001152021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gijtenbeek RGP, Damhuis RAM, van der
Wekken AJ, Hendriks LEL, Groen HJM and van Geffen WH: Overall
survival in advanced epidermal growth factor receptor mutated
non-small cell lung cancer using different tyrosine kinase
inhibitors in The Netherlands: a retrospective, nationwide registry
study. Lancet Reg Health Eur. 27:1005922023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lu X, Yu L, Zhang Z, Ren X, Smaill JB and
Ding K: Targeting EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S)
resistance mutations in NSCLC: Current developments in medicinal
chemistry. Med Res Rev. 38:1550–1581. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shum E, Elamin YY, Piotrowska Z, Spigel
DR, Reckamp KL, Rotow JK, Tan DSW, Lim SM, Kim TM, Lin CC, et al: A
phase 1/2 study of BLU-945 in patients with common activating
EGFR-mutant non-small cell lung cancer (NSCLC): SYMPHONY trial in
progress. J Clin Oncol. 40:TPS91562022. View Article : Google Scholar
|
|
44
|
Wang S, Song Y and Liu D: EAI045: The
fourth-generation EGFR inhibitor overcoming T790M and C797S
resistance. Cancer Lett. 385:51–54. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Takeda M, Okamoto I and Nakagawa K: Pooled
safety analysis of EGFR-TKI treatment for EGFR mutation-positive
non-small cell lung cancer. Lung Cancer. 88:74–79. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Díaz-Serrano A, Gella P, Jiménez E,
Zugazagoitia J and Paz-Ares Rodríguez L: Targeting EGFR in lung
cancer: Current standards and developments. Drugs. 78:893–911.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang L, Li Y, Li L, Wu Z, Yang D, Ma H and
Wang D: The effect of icotinib combined with chemotherapy in
untreated non-small-cell lung cancer that harbored EGFR-sensitive
mutations in a real-life setting: A retrospective analysis. Onco
Targets Ther. 11:2345–2353. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shinomiya S, Kaira K, Yamaguchi O,
Ishikawa K and Kagamu H: Osimertinib induced cardiomyopathy: A case
report. Medicine (Baltimore). 99:e223012020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim
HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et
al: Osimertinib or Platinum-pemetrexed in EGFR T790M-positive lung
cancer. N Engl J Med. 376:629–640. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Montermini L, Meehan B, Garnier D, Lee WJ,
Lee TH, Guha A, Al-Nedawi K and Rak J: Inhibition of oncogenic
epidermal growth factor receptor kinase triggers release of
exosome-like extracellular vesicles and impacts their
phosphoprotein and DNA content. J Biol Chem. 290:24534–24546. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tjin Tham Sjin R, Lee K, Walter AO,
Dubrovskiy A, Sheets M, Martin TS, Labenski MT, Zhu Z, Tester R,
Karp R, et al: In vitro and in vivo characterization of
irreversible mutant-selective EGFR inhibitors that are wild-type
sparing. Mol Cancer Ther. 13:1468–1479. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kobayashi Y and Mitsudomi T: Not all
epidermal growth factor receptor mutations in lung cancer are
created equal: Perspectives for individualized treatment strategy.
Cancer Sci. 107:1179–1186. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hochmair MJ, Morabito A, Hao D, Yang CT,
Soo RA, Yang JC, Gucalp R, Halmos B, Märten A and Cufer T:
Sequential afatinib and osimertinib in patients with EGFR
mutation-positive non-small-cell lung cancer: Final analysis of the
GioTag study. Future Oncol. 16:2799–2808. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Popat S, Jung HA, Lee SY, Hochmair MJ, Lee
SH, Escriu C, Lee MK, Migliorino MR, Lee YC, Girard N, et al:
Sequential afatinib and osimertinib in patients with EGFR
mutation-positive NSCLC and acquired T790M: A global
non-interventional study (UpSwinG). Lung Cancer. 162:9–15. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Miura S, Jung HA, Lee SY, Lee SH, Lee MK,
Lee YC, Hochmair MJ, Yang CT, Märten A, Yang JC, et al: Sequential
afatinib and osimertinib in asian patients with EGFR
Mutation-Positive non-small cell lung cancer and acquired T790M:
Combined analysis of two global non-interventional studies. Onco
Targets Ther. 15:873–882. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Haratake N, Misumi T, Yamanaka T and Seto
T: Optimizing sequential treatment with EGFR tyrosine kinase
inhibitor with a simulation of the T790M mutation rate in
EGFR-mutated lung cancer. JTO Clin Res Rep. 1:1000852020.PubMed/NCBI
|
|
58
|
Hsu PC, Chang JW, Chang CF, Huang CY, Yang
CT, Kuo CS, Fang YF and Wu CE: Sequential treatment in advanced
non-small cell lung cancer harboring EGFR mutations. Ther Adv
Respir Dis. 16:175346662211327312022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
La Monica S, Madeddu D, Tiseo M, Vivo V,
Galetti M, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Falco A,
et al: Combination of gefitinib and pemetrexed prevents the
acquisition of TKI resistance in NSCLC cell lines carrying
EGFR-activating mutation. J Thorac Oncol. 11:1051–1063. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
La Monica S, Minari R, Cretella D,
Flammini L, Fumarola C, Bonelli M, Cavazzoni A, Digiacomo G,
Galetti M, Madeddu D, et al: Third generation EGFR inhibitor
osimertinib combined with pemetrexed or cisplatin exerts
long-lasting anti-tumor effect in EGFR-mutated pre-clinical models
of NSCLC. J Exp Clin Cancer Res. 38:2222019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Stylianopoulos T, Munn LL and Jain RK:
Reengineering the physical microenvironment of tumors to improve
drug delivery and efficacy: From mathematical modeling to bench to
bedside. Trends Cancer. 4:292–319. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Viloria-Petit A, Crombet T, Jothy S,
Hicklin D, Bohlen P, Schlaeppi JM, Rak J and Kerbel RS: Acquired
resistance to the antitumor effect of epidermal growth factor
receptor-blocking antibodies in vivo: A role for altered tumor
angiogenesis. Cancer Res. 61:5090–5101. 2001.PubMed/NCBI
|
|
63
|
Naumov GN, Nilsson MB, Cascone T, Briggs
A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, et al:
Combined vascular endothelial growth factor receptor and epidermal
growth factor receptor (EGFR) blockade inhibits tumor growth in
xenograft models of EGFR inhibitor resistance. Clin Cancer Res.
15:3484–3494. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Cheng Y, Murakami H, Yang PC, He J,
Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, et al:
Randomized Phase II trial of gefitinib with and without pemetrexed
as first-line therapy in patients with advanced nonsquamous
non-small-cell lung cancer with activating epidermal growth factor
receptor mutations. J Clin Oncol. 34:3258–3266. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Han B, Jin B, Chu T, Niu Y, Dong Y, Xu J,
Gu A, Zhong H, Wang H, Zhang X, et al: Combination of chemotherapy
and gefitinib as first-line treatment for patients with advanced
lung adenocarcinoma and sensitive EGFR mutations: A randomized
controlled trial. Int J Cancer. 141:1249–1256. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Hosomi Y, Morita S, Sugawara S, Kato T,
Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, et
al: Gefitinib alone versus gefitinib plus chemotherapy for
non-small-cell lung cancer with mutated epidermal growth factor
receptor: NEJ009 study. J Clin Oncol. 38:115–123. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Miyauchi E, Morita S, Nakamura A, Hosomi
Y, Watanabe K, Ikeda S, Seike M, Fujita Y, Minato K, Ko R, et al:
Updated analysis of NEJ009: Gefitinib-alone versus gefitinib plus
chemotherapy for Non-small-cell lung cancer with mutated EGFR. J
Clin Oncol. 40:3587–3592. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Janne P, Planchard D, Cheng Y, Kulkarni D,
Huang X and Kobayashi K: Osimertinib with/without platinum-based
chemotherapy as first-line treatment in patients with EGFRm
advanced NSCLC (FLAURA2). J Thorac Oncol. 18:S36–S37. 2023.
View Article : Google Scholar
|
|
69
|
Yan X, Wang H, Li P, Zhang G, Zhang M,
Yang J, Zhang X, Zheng X and Ma Z: Efficacy of first-line treatment
with epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) alone or in combination with chemotherapy for advanced
non-small cell lung cancer (NSCLC) with low-abundance mutation.
Lung Cancer. 128:6–12. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY,
Cui JW, Yang N, Song Y, Li XL, Lu S, et al: Bevacizumab plus
erlotinib in Chinese patients with untreated, EGFR-mutated,
advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
Cancer Cell. 39:1279–1291.e1273. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Saito H, Fukuhara T, Furuya N, Watanabe K,
Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori
K, et al: Erlotinib plus bevacizumab versus erlotinib alone in
patients with EGFR-positive advanced non-squamous non-small-cell
lung cancer (NEJ026): Interim analysis of an open-label,
randomised, multicentre, phase 3 trial. Lancet Oncol. 20:625–635.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Nakagawa K, Garon EB, Seto T, Nishio M,
Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, et
al: Ramucirumab plus erlotinib in patients with untreated,
EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
Oncol. 20:1655–1669. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Seto T, Kato T, Nishio M, Goto K, Atagi S,
Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, et al:
Erlotinib alone or with bevacizumab as first-line therapy in
patients with advanced non-squamous non-small-cell lung cancer
harbouring EGFR mutations (JO25567): An open-label, randomised,
multicentre, phase 2 study. Lancet Oncol. 15:1236–1244. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhao H, Yao W, Min X, Gu K, Yu G, Zhang Z,
Cui J, Miao L, Zhang L, Yuan X, et al: Apatinib plus gefitinib as
first-line treatment in advanced EGFR-mutant NSCLC: The phase III
ACTIVE study (CTONG1706). J Thorac Oncol. 16:1533–1546. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Lee Y, Kim HR, Hong MH, Lee KH, Park KU,
Lee GK, Kim HY, Lee SH, Lim KY, Yoon SJ, et al: A randomized Phase
2 study to compare erlotinib with or without bevacizumab in
previously untreated patients with advanced non-small cell lung
cancer with EGFR mutation. Cancer. 129:405–414. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Nishio K, Seto T, Nishio M, Reck M, Garon
EB, Sakai K, Goto K, Kato T, Nakanishi Y, Takahashi T, et al:
Ramucirumab plus erlotinib versus placebo plus erlotinib in
patients with untreated metastatic EGFR-Mutated NSCLC: RELAY
Japanese subset. JTO Clin Res Rep. 2:1001712021.PubMed/NCBI
|
|
77
|
Qi Y, Xia X, Shao L, Guo L, Dong Y, Tian
J, Xu L, Niu R and Wei S: An updated network meta-analysis of
EGFR-TKIs and combination therapy in the first-line treatment of
advanced EGFR mutation positive non-small cell lung cancer. Front
Oncol. 12:6165462022. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zhang G, Yan B, Guo Y, Yang H and Li J:
‘Sandwich’ Strategy to intensify EGFR blockade by concurrent
tyrosine kinase inhibitor and monoclonal antibody treatment in
highly selected patients. Front Oncol. 12:9529392022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Goldberg SB, Redman MW, Lilenbaum R,
Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN,
Melnick MA, et al: Randomized trial of afatinib plus cetuximab
versus afatinib alone for First-Line treatment of EGFR-Mutant
non-small-cell lung cancer: Final results from SWOG S1403. J Clin
Oncol. 38:4076–4085. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Hassanin SO, Hegab AMM, Mekky RH, Said MA,
Khalil MG, Hamza AA and Amin A: Combining in vitro, in vivo, and
network pharmacology assays to identify targets and molecular
mechanisms of spirulina-derived biomolecules against breast cancer.
Mar Drugs. 22:3282024. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Li WQ and Cui JW: Non-small cell lung
cancer patients with ex19del or exon 21 L858R mutation: Distinct
mechanisms, different efficacies to treatments. J Cancer Res Clin
Oncol. 146:2329–2338. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ganti AKP, Loo BW, Bassetti M, Blakely C,
Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M,
et al: Small cell lung cancer, version 2.2022, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
19:1441–1464. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Morgillo F, Della Corte CM, Fasano M and
Ciardiello F: Mechanisms of resistance to EGFR-targeted drugs: Lung
cancer. ESMO Open. 1:e0000602016. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Haratake N, Hayashi H, Shimokawa M, Nakano
Y, Azuma K, Oki M, Ota K, Yoshioka H, Sakamoto T, Yamamoto N, et
al: Phase III Clinical trial for the combination of erlotinib plus
ramucirumab compared with osimertinib in previously untreated
advanced or recurrent non-small cell lung cancer positive for the
L858R mutation of EGFR: REVOL858R (WJOG14420L). Clin Lung Cancer.
23:e257–e263. 2022. View Article : Google Scholar : PubMed/NCBI
|
